{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022291","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2026-05-11T21:21:56+00:00","discovered_at":"2026-05-11T21:24:00.307704+00:00","generated_at":"2026-05-11T21:26:33.622899+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sanara MedTech Q1 net revenue up 19% to $27.8M; GAAP EPS $0.04 vs ($0.07) loss","bullets":["Net income from continuing ops of $0.4M ($0.04 diluted EPS) vs loss of $0.6M ($0.07) YoY.","Adjusted EBITDA $4.3M (+58% YoY); gross margin improved to 93% from 92%.","Soft tissue repair revenue rose 21% to $24.9M; bone fusion revenue essentially flat at $2.9M.","Q2 2026 revenue guidance $28.5M-$29.5M (10-14% growth); full-year 2026 reaffirmed at $116M-$121M.","Sales team expanded to 43 reps; products contracted at >4,000 U.S. facilities; cash $13.6M, debt $46.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022291","json":"https://secwatch.observer/filing/0001493152-26-022291.json","markdown":"https://secwatch.observer/filing/0001493152-26-022291.md","text":"https://secwatch.observer/filing/0001493152-26-022291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/0001493152-26-022291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T21:26:33.622899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60d0d3f09645c31b2ed197673aaac907900bc9bf","claim":"Sanara MedTech Inc. reported the first quarter ended March 31, 2026 results: revenue $27.8 million, net income $0.4 million, EPS $0.04 per diluted share.","evidence_excerpt":"in the surgical market, today reported its financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary (1) ● Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025. ● Gross profit of $25.9 million, or 93% of net revenue, compared to gross profit of $21.6 million, or 92% of net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/0001493152-26-022291-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$27.8 million"},{"label":"Net income","value":"$0.4 million"},{"label":"EPS","value":"$0.04 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}